Name: Latest research reports of Zydus Lifesciences Ltd. authored by Phillip Capital and published by - Trendlyne research reports.
Item: Zydus Lifesciences Ltd.
Rating: 5
Author: Phillip Capital

Zydus Lifesciences Ltd.

NSE: ZYDUSLIFE | BSE: 532321 | ISIN: INE010B01027 | Industry: Pharmaceuticals
| Mid-range Performer

975.0000 -44.25 (-4.34%)

NSE Sep 26, 2025 15:31 PM

Volume: 2.6M

High volume today

Zydus Lifesciences Ltd.

16 May 2016

975.00

-4.34%

Cadila Q4FY16 Update 16May2016

Buy: Zydus Lifesciences Ltd.

Recommendation

Phillip Capital

9 JV business saw strong 25%/14% growth for Q4/FY16. However, it guides for flattish revenueperformancefromitsJVbusinessinFY17 9 CDHindicatestocompletelargepartofremedialactionsbyMay2016atitsproblematic...

Zydus Lifesciences Ltd. is trading below its 30 day SMA of 1013.0